Compare RUMBW & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RUMBW | YDESW |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 156 | 15 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | RUMBW | YDESW |
|---|---|---|
| Price | $1.77 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.5K | 8.6K |
| Earning Date | 03-28-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,651,775.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $0.76 | $0.20 |
| 52 Week High | $3.72 | $2.85 |
| Indicator | RUMBW | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 41.16 |
| Support Level | $1.31 | N/A |
| Resistance Level | $1.83 | $0.35 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 29.55 | 37.90 |
RUM Group Inc focused is to maximize the power of human imagination through an independent technology ecosystem built on privacy, resilience, and an open alternative to Big Tech. Rumble gives human creativity a voice, a video and media platform built for creators and audiences who value free expression. Quake AI is a cloud and AI-infrastructure business, delivering the compute, data-center capacity, and blockchain infrastructure for the agentic era.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.